Variant report
Variant | esv3434397 |
---|---|
Chromosome Location | chr5:27584244-27599518 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs10072472 | chr5:27592048-27592049 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
2 | rs373539911 | chr5:27592086-27592087 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs548647041 | chr5:27592100-27592101 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs567158904 | chr5:27592128-27592129 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs10057484 | chr5:27592140-27592141 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
6 | rs184954832 | chr5:27592149-27592150 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs372351690 | chr5:27592181-27592182 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs189736311 | chr5:27592189-27592190 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs72739460 | chr5:27592209-27592210 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
10 | rs192654201 | chr5:27592214-27592215 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs573186875 | chr5:27592230-27592231 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs75344044 | chr5:27592257-27592258 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs184550277 | chr5:27592289-27592290 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs574146058 | chr5:27592306-27592307 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs114356251 | chr5:27592355-27592356 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs563061917 | chr5:27592362-27592363 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs115264433 | chr5:27592386-27592387 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs545681724 | chr5:27592465-27592466 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
19 | rs559921805 | chr5:27592475-27592476 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
20 | rs527278296 | chr5:27592482-27592483 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
21 | rs548536066 | chr5:27592492-27592493 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
22 | rs534907834 | chr5:27592494-27592495 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
23 | rs531259435 | chr5:27592521-27592522 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
24 | rs189289205 | chr5:27592594-27592595 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
25 | rs141328677 | chr5:27592618-27592619 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
26 | rs552727385 | chr5:27592630-27592631 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
27 | rs144677641 | chr5:27592660-27592661 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
28 | rs2329658 | chr5:27592712-27592713 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
29 | rs181905338 | chr5:27592772-27592773 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
30 | rs559051964 | chr5:27592789-27592790 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
31 | rs577541447 | chr5:27592791-27592792 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
32 | rs534197443 | chr5:27592823-27592824 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
33 | rs138621043 | chr5:27592849-27592850 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
34 | rs386686571 | chr5:27592868-27592869 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
35 | rs2329660 | chr5:27592870-27592871 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
36 | rs185686383 | chr5:27592871-27592872 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
37 | rs545414041 | chr5:27592988-27592989 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
38 | rs201761399 | chr5:27593006-27593007 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
39 | rs189027952 | chr5:27593070-27593071 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
40 | rs572376918 | chr5:27593081-27593082 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs542218704 | chr5:27593094-27593095 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
42 | rs200122155 | chr5:27593155-27593156 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
43 | rs181857138 | chr5:27593236-27593237 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs531344560 | chr5:27593242-27593243 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs555040740 | chr5:27593309-27593310 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs141618350 | chr5:27593310-27593311 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
47 | rs564959425 | chr5:27593313-27593314 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs532318159 | chr5:27593334-27593335 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs539011430 | chr5:27593344-27593345 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
50 | rs150304230 | chr5:27593379-27593380 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Chronic lymphocytic leukemia | 21546498 | CNVD |
Salivary gland tumor | 18059337 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Kartagener syndrome | 16639409 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Cervical squamous cell carcinoma | 21590768 | CNVD |
Non-small cell lung cancer | 20864512 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Medulloblastoma | 16783165 | CNVD |
Thyroid cancer | 19087340 | CNVD |
Liposarcoma | 21253554 | CNVD |
Pancreatic endocrine tumor | 17639061 | CNVD |
Cervical Cancer | 21857958 | CNVD |
Cervical cancer | 21062161 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Oral cancer | 21386901 | CNVD |
Astrocytoma | 17387387 | CNVD |
Breast cancer | 21264507 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Esophageal squamous carcinoma | 18350619 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Malignant mesothelioma | 18160781 | CNVD |
Pleural malignant mesothelioma | 18160781 | CNVD |
Cervical cancer | 18559093 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Acute lymphoblastic leukemia | 17690704 | CNVD |
Gastrointestinal stromal cancer | 16982739 | CNVD |
Phyllodes tumor | 17334353 | CNVD |
Malaria | 21533027 | CNVD |
Renal cell carcinoma | 19461508 | CNVD |
Colorectal cancer | 21645411 | CNVD |
Gastric cancer | 22152101 | CNVD |
Oesophago-gastric ulcer | 22152101 | CNVD |
Ovarian cancer | 21781307 | CNVD |
Breast cancer | 20668451 | CNVD |
Cancer | 20668451 | CNVD |
Lung cancer | 20668451 | CNVD |
Ovarian cancer | 20668451 | CNVD |
Pancreas cancer | 20668451 | CNVD |
Prostate cancer | 20668451 | CNVD |
Cancer | 20164919 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Multiple myeloma | 17550852 | CNVD |
prenatal diagnosis | 22389664 | CNVD |
Bladder cancer | 21909424 | CNVD |
DNA damage stimulus | 22844521 | CNVD |
DNA repair | 22844521 | CNVD |
Breast cancer | 21785460 | CNVD |
Spinal muscular atrophy | 22422766 | CNVD |
Spinal muscular atrophy | 22558076 | CNVD |
Spinal muscular atrophy | 21320981 | CNVD |
Spinal muscular atrophy | 21762474 | CNVD |
Breast cancer | 21858162 | CNVD |
Esophageal adenocarcinoma | 19417022 | CNVD |
Cancer | 16751803 | CNVD |
Breast cancer | 16608533 | CNVD |
Autism | 22495311 | CNVD |
Melanoma | 18172304 | CNVD |
Non-syndromic sensorineural hearing loss | 20606397 | CNVD |
Intellectual disability | 22102821 | CNVD |
Lung cancer | 16740712 | CNVD |
Renal cell carcinoma | 18194544 | CNVD |
Prostate cancer | 21965145 | CNVD |
Cancer | 21183584 | CNVD |
Ovarian cancer | 20844748 | CNVD |
Myeloproliferative neoplasm | 20015882 | CNVD |
Breast cancer | 17603634 | CNVD |
Gastrointestinal stromal cancer | 20818650 | CNVD |
Non-small cell lung cancer | 19010865 | CNVD |
Glioblastoma multiforme | 22286061 | CNVD |
Compulsive disorder | 18923513 | CNVD |
Epilepsy | 18923513 | CNVD |
Prader-willi syndrome | 18923513 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Ovarian cancer | 21720365 | CNVD |
Lung cancer | 18438408 | CNVD |
Glioma | 20126413 | CNVD |
Non-small cell lung cancer | 21829676 | CNVD |
Breast cancer | 22032731 | CNVD |
Esophageal cancer | 20955586 | CNVD |
Prostate cancer | 18632612 | CNVD |
Breast cancer | 21364760 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr5:27592000-27592400 | Enhancers | hESC Derived CD56+ Mesoderm Cultured Cells | ES cell derived |
2 | chr5:27592000-27592800 | Enhancers | NH-A | brain |
3 | chr5:27592400-27593200 | Weak transcription | hESC Derived CD56+ Mesoderm Cultured Cells | ES cell derived |
4 | chr5:27592400-27593600 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
5 | chr5:27593200-27593400 | Enhancers | hESC Derived CD56+ Mesoderm Cultured Cells | ES cell derived |
6 | chr5:27593400-27594400 | Weak transcription | hESC Derived CD56+ Mesoderm Cultured Cells | ES cell derived |
7 | chr5:27594400-27594600 | Enhancers | hESC Derived CD56+ Mesoderm Cultured Cells | ES cell derived |